The EORTC contributed to the trial design and will assist ImmunoCellular Therapeutics in facilitating accrual of patients for this trial in Europe.
EORTC Brain Tumor Group chairman and coordinator of this study Michael Weller said: "The EORTC is a leader in enabling multi-disciplinary approaches to investigate strategic therapeutic questions through clinical and translational research.
"We aim to improve the understanding of disease and help advance innovative therapies in cancer care for the benefit of patients. We are pleased to collaborate with ImmunoCellular to conduct the phase 3 registrational trial of ICT-107, a potentially promising cancer immunotherapeutic approach to treating brain cancer."
ImmunoCellular CEO Andrew Gengos said: "Working with the EORTC is a key step in our strategy to establish a network of relationships within the clinical oncology community to support the conduct of the ICT-107 Phase 3 trial.
"For several months, we have been working with prominent cancer cooperative groups in the US and Europe to refine and finalize the trial design, gain their endorsement and secure their help in executing a high quality trial. With EORTC’s support, we believe that we can access large numbers of affiliated trial sites which will facilitate patient accrual. We anticipate patient enrollment in the phase 3 trial to begin within the next few weeks."